administration barred government agencies buying certain drugs abbott laboratories charging company failed correct violations quality standards suburban chicago plant would approve applications north chicago-based pharmaceutical giant involve certain products plant letter abbott dated march released until tuesday company products adulterated because improper manufacturing practices agency district director chicago raymond mlecko investigators unsterile products plant violations federal manufacturing requirements letter warned prepared severe measures including seizing products shutting manufacturing operations abbott quickly correct alleged problems donald wright abbott corporate president quality assurance action resulted misunderstanding about extent which worked correct problems wright problems should remedied would material effect abbott health industry analyst michael harshbarger chicago letter ominous implications wrist report november cited abbott plant failure maintain proper sterilty failure follow quality problems least making improper changes records designed approved manner drugs involved antibiotic called erythrocin lactobionate batch anti-inflammatory steroid under brand a-methapred given patients hospitals treat severe arthritis lupus chronic inflammation tissue around joints mlecko there evidence problems immediate public health
